Cui T-J, Lin G-S, Dai Y-M, Zheng J-P, Chen Z, Chen Q, Zheng Y, Lin X
Department of Medical Oncology, Fujian Provincial Hospital, Fuzhou, China.
Eur Rev Med Pharmacol Sci. 2019 Aug;23(3 Suppl):264-273. doi: 10.26355/eurrev_201908_18656.
Previous studies have shown that long non-coding RNA (lncRNA) HOXA-AS2 is a cancer-promoting gene. However, the role of HOXA-AS2 in non-small cell lung cancer (NSCLC) has not been reported. This study aims to investigate the expression characteristics of HOXA-AS2 in NSCLC and whether HOXA-AS2 can promote the malignant progression of NSCLC by regulating microRNA-216a-5p.
Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was used to examine the HOXA-AS2 level in 40 pairs of NSCLC tumor tissue samples and adjacent ones. Then, the relationship between HOXA-AS2 expression and clinical indicators and prognosis of NSCLC was analyzed. Meanwhile, qRT-PCR further verified the expression level of HOXA-AS2 in NSCLC cell lines. Also, HOXA-AS2 knockdown and overexpression models were constructed using lentivirus in NSCLC cell lines, and the effects of HOXA-AS2 on the biological function of NSCLC cells were analyzed using the Cell Counting Kit-8 (CCK-8), transwell migration, and cell wound healing assays. Finally, Western blotting assay and cell recovery experiment were used to explore the regulatory mechanism of HOXA-AS2 and microRNA-216a-5p in NSCLC.
In this experiment, qRT-PCR results revealed that HOXA-AS2 level in NSCLC tumor tissue specimens was remarkably higher than that in adjacent tissues. Compared with those with low expression of HOXA-AS2, the patients with high expression had a higher incidence of distant metastases and a lower overall survival rate. The proliferative and metastasis abilities of the cells in the HOXA-AS2 overexpression group were remarkably increased when compared with the control group, while the opposite results were observed in HOXA-AS2 silence group. Subsequently, qRT-PCR verified that microRNA-216a-5p level was remarkably decreased in NSCLC tissues and negatively correlated with HOXA-AS2 expression. In addition, the result of the cell recovery experiment and Western blotting revealed that there might be a mutual regulation between HOXA-AS2 and microRNA-216a-5p, the two of which could jointly regulate the malignant progression of NSCLC.
The results indicate that lncRNA HOXA-AS2 is upregulated in NSCLC and is remarkably associated with distant metastasis and poor prognosis of NSCLC patients. In addition, lncRNA HOXA-AS2 is found to be able to promote the malignant progression of NSCLC via regulating microRNA-216a-5p.
既往研究表明长链非编码RNA(lncRNA)HOXA-AS2是一种促癌基因。然而,HOXA-AS2在非小细胞肺癌(NSCLC)中的作用尚未见报道。本研究旨在探讨HOXA-AS2在NSCLC中的表达特征,以及HOXA-AS2是否能通过调控微小RNA-216a-5p促进NSCLC的恶性进展。
采用定量实时聚合酶链反应(qRT-PCR)检测40对NSCLC肿瘤组织样本及其癌旁组织中HOXA-AS2的水平。然后,分析HOXA-AS2表达与NSCLC临床指标及预后的关系。同时,qRT-PCR进一步验证HOXA-AS2在NSCLC细胞系中的表达水平。此外,利用慢病毒在NSCLC细胞系中构建HOXA-AS2敲低和过表达模型,并采用细胞计数试剂盒-8(CCK-8)、transwell迁移实验和细胞划痕愈合实验分析HOXA-AS2对NSCLC细胞生物学功能的影响。最后,采用蛋白质免疫印迹法和细胞回复实验探讨HOXA-AS2与微小RNA-216a-5p在NSCLC中的调控机制。
在本实验中,qRT-PCR结果显示NSCLC肿瘤组织标本中HOXA-AS2水平显著高于癌旁组织。HOXA-AS2高表达患者的远处转移发生率高于低表达患者,总生存率低于低表达患者。与对照组相比,HOXA-AS2过表达组细胞的增殖和转移能力显著增强,而HOXA-AS2沉默组则出现相反结果。随后,qRT-PCR验证NSCLC组织中微小RNA-216a-5p水平显著降低,且与HOXA-AS2表达呈负相关。此外,细胞回复实验和蛋白质免疫印迹结果显示HOXA-AS2与微小RNA-216a-5p之间可能存在相互调控,二者共同调控NSCLC的恶性进展。
结果表明lncRNA HOXA-AS2在NSCLC中上调,且与NSCLC患者的远处转移和不良预后显著相关。此外,发现lncRNA HOXA-AS2能够通过调控微小RNA-216a-5p促进NSCLC的恶性进展。